Key facts
- EncephalX’s last known valuation is $9.6M (Feb 2026).
- It has raised $2.7M; the latest was Seed Round ($2.3M) in Feb 2026.
- Notable investors include Investissement Quebec, Front Row Ventures, Angels Capital, ACET, Anges Québec — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for EncephalX
- ·The full record, as it builds
Funding rounds
No funding rounds for EncephalX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EncephalX
Developer of cranial implants designed to reduce the risk of complications for patients treated for head trauma, stroke, or subdural hematoma. The company's platform offers a variety of features, including a dynamic cranioplasty system that allows the skull to expand as the brain heals, reducing the need for additional surgery, enabling neurosurgeons to provide patients with a quality of life and reduce the overall cost of care.
- Sector
- Healthcare
- HQ
- Sherbrooke, Canada
- Founded
- 2020
- Employees
- 5
- Website
- encephalx.ca/
- Ownership
- Privately Held (backing)
EncephalX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EncephalX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EncephalX in its N-PORT filings yet. We sweep new filings monthly.